L'Agence nationale de la recherche Des projets pour la science

Investissements d'avenirProjets financés

Nucléaire pour la Santé (ARRONAXPLUS)

Action : Equipements d'excellence

N° de convention : 11-EQPX-0004

Informations générales

  • Référence projet : 11-EQPX-0004
  • Etablissement Coordinateur : GIP ARRONAX
  • Région du projet : Pays de la Loire
  • Discipline : 5 - Bio Med
  • Aide allouée : 8 007 340 €
  • Date de début du projet : 01/05/2012
  • Date de fin du projet : 31/12/2019
  • Site web du projet : http://www.cyclotron-nantes.fr/spip.php?rubrique81&lang=fr
  • Mots clés : Nuclear Medicine; radiopharmaceuticals; Radiation interaction with matter

Résumé du projet

The aim of ArronaxPlus is to develop new radio-medicines for a better effectiveness of molecular imaging and of the treatment of pathologies such as cancer. A multidisciplinary consortium going from physics to nuclear medicine, including chemistry and biology, has been set up. ArronaxPlus has made possible to set up four high-level technological platforms(PST): PST 1: Production of radionuclides is built around the Arronax multi-particle, high-energy, high-energy cyclotron (unique in the world) and allows the production of innovative radionuclides not yet used in clinical routine. PST 2: Chemistry and radiopharmaceuticals is based on the skills and materials of the consortium's chemistry groups: quantum computations, fundamental chemistry, and development of innovative radiolabelling methods, set up of a production unit for experimental radioactive drugs in collaboration with the CHU of Nantes (APUI). PST 3: Preclinical and clinical trials (therapy and imaging): Set-up of a multimodal rodent imaging center (CIMA) including a 3-photons unique imaging modality and an imaging center for domestic carnivores and monkeys (CEMA). Preparation of clinical trials. PST 4: Living and inert matter under radiation offers the possibility of controlled irradiation of inert and biological materials (living cells) in order to study the effects of irradiation for 2 main fields of application: nuclear waste management and health These platforms are operational since mid-2016 and are open to academic and industrial researchers. A training program have been designed in collaboration with the IRON labex. In conclusion, ArronaxPlus is a viable project promoting the development of new radiopharmaceuticals for diagnosis or therapy within the framework of a strong academic program (labex IRON, ISITE NEXT) in the view of setting up, with the competitiveness cluster Atlanpole Biotherapies, a nuclear for health cluster that includes the private sector.  

(L'auteur de ce résumé est le coordinateur du projet, qui est responsable du contenu de ce résumé. L'ANR décline par conséquent toute responsabilité quant à son contenu.)